Pfizer signs antiviral COVID-19 licence with MPP

Pfizer is the latest pharmaceutical company to sign a licensing agreement with the Medicines Patent Pool (MPP) to help increase access to its COVID-19 oral antiviral treatment candidate PAXLOVID (PF-07321332) for low and middle-income countries.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Takeda sees off UK challenge to Elvanse SPC

28 September 2026 Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

More features

Westlaw publisher scores landmark AI copyright win in US appeals court

Scientist and Chinese biotech targeted by Beam in secrets suit

Clifford Chance recruits new head of Asia-Pac

Takeda sees off UK challenge to Elvanse SPC

Conley Rose welcomes back former employee with legal and business nous

Mylan throws down new gauntlet in Novo Wegovy patent fight

Novartis defeats Orange Book challenge but suffers EU setback

New UK High Court judge named as replacement for Justice Meade

Pfizer signs antiviral COVID-19 licence with MPP

More on this story

Editor's picks

Editor's picks

More features